Elasmogen Ltd

Elasmogen, a spin-out from the University of Aberdeen, is a drug discovery and development, biopharmaceutical company developing soloMERs, fully humanized, next generation, single chain biologics for auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical candidates derived from VNARS (variable new-antigen receptors) which exist naturally in sharks as high affinity binding domains. With a different ancestral origin from antibodies this example of 400 million year old convergent evolution places VNARs outside of the complex patent landscape that describes and protects antibody drug discovery. soloMERs are the smallest (9% of the size of an antibody) and most robust naturally occurring binding domain which makes them ideal for binding to intracellular targets. The Company’s technology has been endorsed through partnerships with Almac, Amgen and Merck.

Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, products and process including an exclusive license to over 20 patents granted in the US, Europe and other territories together with the entire know-how and VNAR pipeline from the Scottish Biologics Facility, University of Aberdeen.